TPL Path Labs
TPL Path Labs is a privately held, GLP-compliant histopathology contract research organization based in Freiburg, Germany, providing histology, pathology evaluation, necropsy, and specimen archiving services to biopharmaceutical and medical device developers for regulatory submissions. It now operates within StageBio.
- Company typePrivate
- Founded2008
- HeadquartersFreiburg, Germany
- Headcount11–50
- GTM typeB2B
- OfferingServices
What TPL Path Labs does
TPL Path Labs is a privately held, GLP-compliant contract research organization (CRO) founded in 2008 and headquartered in Freiburg, Germany, providing specialized histopathology services to the biopharmaceutical and medical device industries. Its core offering spans an integrated laboratory workflow including tissue processing and histology, board-certified pathology evaluation, animal necropsy for toxicology and safety-assessment studies, and biorepository/specimen archiving for long-term research material retention. The company serves three customer segments — biopharmaceutical companies (primary), medical device developers (primary), and academic/research institutions (secondary) — whose common need is regulatory-ready histopathology data for FDA and international submissions.
The underlying service model is B2B and project-based: clients engage TPL Path Labs for specific preclinical, translational, or regulatory-submission studies, with pricing handled on a quote basis rather than through publicly disclosed rates. Technically, the differentiation rests on GLP-compliant operations, board-certified pathologist oversight, specialized toxicologic pathology expertise, and an end-to-end workflow from necropsy through pathology evaluation to archiving. The company is no longer operating as an independent entity following its acquisition by StageBio (itself owned by HSRL Holdings LLC), and now operates as part of StageBio's transatlantic GLP-compliant histopathology platform, with combined US (Frederick, MD; Maurertown, VA) and European (Freiburg) footprint serving drug and device developers from discovery through regulatory submission.
Revenue mechanics are not publicly disclosed; the company does not report revenue, has no funding rounds on record, and operates with a headcount in the 11–50 range consistent with a small specialty CRO. Marketing and demand generation are handled through StageBio's infrastructure — industry events (AAIC 2026, EuroTox 2026), webinars, content marketing, LinkedIn presence, and a quarterly newsletter — rather than through TPL Path Labs' own standalone channels.
TPL Path Labs firmographics
Firmographics- Name
- TPL Path Labs
- Legal name
- TPL Path Labs
- Website
- https://tpl-path-labs.com
- Company type
- Private
- Founded year
- 2008
- Operating status
- Acquired
- Headcount range
- 11–50 employees
- Short description
- TPL Path Labs is a privately held, GLP-compliant histopathology contract research organization based in Freiburg, Germany, providing histology, pathology evaluation, necropsy, and specimen archiving services to biopharmaceutical and medical device developers for regulatory submissions. It now operates within StageBio.
- Ownership category
- akta.pro rank
TPL Path Labs industry classification
Industry- Product category
- Histopathology Laboratory Services
- NAICS
- Research and Development in the Physical, Engineering, and Life Sciences (54171), Testing Laboratories and Services (541380)
- SIC
- Services-Commercial Physical & Biological Research (8731), Services-Testing Laboratories (8734)
- akta.pro primary industry
- Toxicology & Safety Assessment CROs (GLP) (HLAGAAAC)
- akta.pro secondary industry
- Data Management, Reporting & Regulatory Submissions for Central Labs (HLAGAEAL)
Keywords
Where TPL Path Labs is headquartered
LocationHeadquarters
- HQ city
- Freiburg
- HQ country
- Germany
- HQ region
- Europe
Markets served
TPL Path Labs business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Infrastructure, Technology or R&D
Distribution channels1 record
Marketing channels5 records
TPL Path Labs product offering
Product offeringCore offering
TPL Path Labs is an independent contract research organization (CRO) providing GLP-compliant histopathology laboratory services for preclinical and translational research. Its offerings include histology, tissue processing and staining, pathology evaluation by board-certified pathologists, animal necropsy services for toxicology studies, and specimen biorepository/archiving. The company primarily supports biopharmaceutical and medical device developers preparing regulatory submissions.
Product overview
TPL Path Labs provides histopathology laboratory services as part of the global histopathology services market. The company operates in a market segment projected to grow from US$23,890.44 million in 2021 to US$35,187.90 million by 2028. TPL Path Labs has been acquired by StageBio, expanding StageBio's histopathology capabilities across North America and Europe.
Differentiator
Problem solved
Functional benefit
Products and services
- Histology and Tissue Processing Tissue processing, sectioning, and staining services for preclinical and clinical research, delivered as a GLP-compliant service for biopharma and medical device developers requiring regulatory-ready data.
- Pathology Evaluation Board-certified pathologist evaluation and diagnostic services supporting toxicology studies, safety assessment, and regulatory submissions for drug and device developers.
- Necropsy Services Animal necropsy services supporting toxicology and safety assessment studies for preclinical drug and medical device programs.
- Biorepository and Specimen Archiving Specimen storage and archival services for long-term preservation of research materials supporting preclinical, translational, and clinical research programs.
Companies that use TPL Path Labs
Customer profileSegments3 records
Ideal customer profiles2 records
TPL Path Labs technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
TPL Path Labs partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- StageBiocoreStageBio expanded its capabilities on both sides of the Atlantic through the acquisition of TPL Path Labs. This acquisition integrated TPL Path Labs into StageBio's GLP-compliant CRO operations, combining histopathology, necropsy, pathology, and archiving services. The partnership enables biopharma and medical device developers to access expanded service capabilities for regulatory submissions.
Scale indicators2 records
Recent moves3 records
Expansion highlights4 records
TPL Path Labs competitors and assessment
Company assessmentBroad incumbents
- WuXi AppTec: Global CRO/CDMO with extensive preclinical pathology, toxicology, and safety assessment capabilities serving biopharma clients — directly overlapping TPL Path Labs' core GLP histopathology offering.
- Charles River Laboratories: Large global CRO with established histopathology, toxicology, and safety assessment services. Provides bundled discovery-to-clinical offerings that compete with TPL Path Labs on preclinical toxicologic pathology work for biopharma clients.
- Sonic Healthcare: Global diagnostics provider including anatomic pathology and histology services. Listed alongside TPL Path Labs in histopathology services market analysis, with broader geographic and modality reach.
- UNILABS: European clinical diagnostics and specialty laboratory services provider with histopathology capabilities. Mentioned as a market peer in industry histopathology services reports covering TPL Path Labs' category.
- ICON plc (PRA Health): Global CRO offering preclinical and clinical laboratory services including central lab and histology support, competing for the same biopharma and medical device safety assessment engagements as TPL Path Labs.
- LabCorp (Covance): Major diagnostic and CRO services provider offering preclinical histopathology, central lab, and clinical trial testing — directly overlapping TPL Path Labs' GLP histopathology work as part of a broader services portfolio.
Direct peers
- Targos: Hamburg-based specialty CRO providing clinical trial biomarker services, central laboratory testing, and histopathology. Cited alongside TPL Path Labs as a competitor in the histopathology services market analysis.
- StageBio: Parent company and direct operator of the same GLP-compliant histopathology, necropsy, and biorepository services following the acquisition of TPL Path Labs. Operates US sites in Frederick, MD and Maurertown, VA with identical service offerings.
Emerging players
- HistoBridge: Specialty histopathology services provider focused on supporting preclinical research and GLP studies, comparable in scope and target customer base to TPL Path Labs' Freiburg operations.
- HistoWiz: Specialty histology and digital pathology service provider for academic and biopharma researchers. Comparable to TPL Path Labs in core histology/IHC service line, though focused more on translational research than GLP toxicology.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat3 records
Key risks5 records
Key highlights5 records
Customer concentration
TPL Path Labs financial estimates
Financial estimateRevenue estimate
Valuation estimate
TPL Path Labs leadership team
Management profileNumber of profiles
TPL Path Labs funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
TPL Path Labs M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about TPL Path Labs
What does TPL Path Labs do?
TPL Path Labs is an independent contract research organization (CRO) providing GLP-compliant histopathology laboratory services for preclinical and translational research. Its offerings include histology, tissue processing and staining, pathology evaluation by board-certified pathologists, animal necropsy services for toxicology studies, and specimen biorepository/archiving. The company primarily supports biopharmaceutical and medical device developers preparing regulatory submissions.
Is TPL Path Labs a public or private company?
TPL Path Labs is a private company. It is classified as corporate owned and is currently acquired.
When was TPL Path Labs founded?
TPL Path Labs was founded in 2008. It employs 11 to 50 people.
Where is TPL Path Labs based?
TPL Path Labs is headquartered in Freiburg, Germany, in the Europe region.
Who are TPL Path Labs's main competitors?
Broad incumbents on record are WuXi AppTec, Charles River Laboratories, Sonic Healthcare, UNILABS, ICON plc (PRA Health) and LabCorp (Covance). Direct peers are Targos and StageBio. Emerging players are HistoBridge and HistoWiz.
Does TPL Path Labs have an API?
No public API is recorded for TPL Path Labs.
What industry is TPL Path Labs in?
TPL Path Labs's product category is Histopathology Laboratory Services. Its primary akta.pro industry code is HLAGAAAC, Toxicology & Safety Assessment CROs (GLP), with a secondary code of HLAGAEAL, Data Management, Reporting & Regulatory Submissions for Central Labs. Its NAICS code is 54171 and its SIC code is 8731.